Thus we analyzed three different types of mouse HCC models driven by MYC overexpression: the transplantable hepatoblast model where p53-/- hepatoblasts were retrovirally transduced with a MYC overexpression plasmid, a hepatoblastoma model where tail-vein injection is used to delivery a TET-inducible MYC transgene directly into liver cells (the presumed cell-of-origin was deduced from histological analysis of the resultant tumors[4]), and a classic transgenic model where the hepatocyte-specific ALB promoter is used to drive MYC expression. Here, ALB is linked to hepatocellular carcinoma.